GSK's Garnier to join Dubai equity firm

Wondering what Jean-Pierre Garnier will do with his free time when he steps down as GlaxoSmithKline's head honcho in May? Wonder no more. The CEO was just appointed to the advisory board of Dubai International Capital's global strategic equities fund, which buys stock in public companies.

Garnier will be in good company. The former heads of Sony and BMW were also tapped as advisors to the firm, which is owned by Dubai ruler Sheikh Mohammed bin Rashid Al Maktoum. The men will be charged with identifying investment targets and helping to bring in new deals.

It's not an earth-shatteringly novel move, joining a private equity firm after checking out of a CEO suite. But where top execs once hooked up with Western firms like Carlyle, now, Asian and Middle Eastern groups are attracting top talent.

- see the release from Dubai International Capital
- read this Financial Times article

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.